| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bullish stance on Merck & Co.
Looking at options history for Merck & Co (NYSE:MRK) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $157,700 and 6, calls, for a total amount of $517,740.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $120.0 to $130.0 for Merck & Co over the recent three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Merck & Co's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck & Co's significant trades, within a strike price range of $120.0 to $130.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRK | CALL | TRADE | BULLISH | 01/17/25 | $15.45 | $15.45 | $15.45 | $120.00 | $309.0K | 2.4K | 12 |
| MRK | PUT | SWEEP | BULLISH | 01/16/26 | $7.35 | $7.1 | $7.1 | $120.00 | $85.2K | 1.5K | 205 |
| MRK | PUT | SWEEP | BEARISH | 06/14/24 | $0.62 | $0.53 | $0.58 | $129.00 | $72.5K | 188 | 9 |
| MRK | CALL | TRADE | BULLISH | 01/17/25 | $9.3 | $9.05 | $9.2 | $130.00 | $70.8K | 3.6K | 83 |
| MRK | CALL | SWEEP | BULLISH | 06/07/24 | $5.35 | $5.2 | $5.31 | $126.00 | $52.9K | 1.9K | 203 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck & Co, we pivot to a closer look at the company's own performance.
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $155.0.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Merck & Co options trades with real-time alerts from Benzinga Pro.
Posted In: MRK
